Radiation & Tissue Effects in the Genitourinary Tract
Radiation therapy for pelvic malignancies — prostate, cervical, endometrial, rectal, and bladder cancers — produces both acute and chronic genitourinary complications through vascular injury, progressive fibrosis, and irreversible tissue damage. The pathophysiology involves endothelial cell death, endarteritis obliterans, urothelial barrier disruption, and progressive tissue hypoxia that manifests as urinary dysfunction, sexual impairment, and structural complications requiring complex reconstructive approaches.[1][2][3]
For the reconstructive urologist, radiation history fundamentally changes the operative environment: irradiated tissue is hypovascular, hypocellular, and hypoxic — it heals poorly, fails grafts, and cannot reliably support tissue repair without importing non-irradiated, well-vascularized tissue from outside the field.
Radiation Modalities and Their GU Toxicity Profiles
| Modality | Description | GU Toxicity Profile |
|---|---|---|
| External beam radiotherapy (EBRT) | Conventional fractionation (1.8–2.0 Gy/fraction × 44–50 fractions) | Moderate acute irritative symptoms; late fibrosis/stricture risk |
| Intensity-modulated RT (IMRT) | Computer-optimized dose delivery; conformal dose shaping | Lower rectal/bladder dose compared to 3D-CRT; current standard for prostate RT |
| Brachytherapy (LDR/HDR) | Radioactive seeds or temporary catheters placed within/adjacent to prostate | Higher urethral dose; higher stricture rates; ASCENDE-RT: 18.4% stricture vs 5.2% EBRT alone[1] |
| SBRT/SABR | Ultra-hypofractionation (6.1–7.25 Gy/fraction × 5 fractions) | Worse transient acute GU toxicity than conventional fractionation; once-weekly dosing shows superior acute urinary QoL[1] |
| Proton beam | Charged particle therapy; Bragg peak limits exit dose | Theoretical bladder/rectal sparing; clinical GU toxicity data still maturing |
| Combined modality | Surgery + adjuvant/salvage RT | Highest risk for outlet complications, stricture, and incontinence[10][11] |
Pathophysiology of Radiation-Induced Tissue Damage
Radiation injury occurs through distinct temporal phases driven by different biological mechanisms:[1][4]
Acute Toxicity (During Treatment Through 3–6 Months)
Acute effects result from direct damage to rapidly dividing cells — urothelium, bowel mucosa, and skin. The urothelium, normally replaced every 6 months, turns over more rapidly under radiation stress, generating reactive inflammation. Approximately 50% of patients experience irritative voiding symptoms (frequency, urgency, dysuria) during pelvic radiation.[1]
- Urothelial inflammation and mucositis — direct mucosal injury; barrier dysfunction
- Edema and vascular congestion — submucosal inflammatory infiltrate
- Smooth muscle spasm — contributes to urgency and frequency
- Acute reactions typically resolve within 4–6 weeks after treatment completion with regeneration of surviving urothelial stem cells[1]
Late Toxicity (≥6 Months Post-Treatment)
Late effects stem from microvascular damage and fibroblast dysfunction in slowly dividing tissues — the dominant mechanism of chronic GU morbidity:[1][4][5]
- Endarteritis obliterans — progressive occlusion of small arterioles, reducing tissue perfusion
- Submucosal fibrosis — replacement of vascular stroma with hypocellular collagen
- Telangiectasia formation — fragile superficial vessels prone to hemorrhage (source of radiation hematuria)
- Progressive hypoxia — creates a self-perpetuating cycle of poor healing and tissue necrosis
- Urothelial barrier disruption — loss of E-cadherin, ZO-1, and uroplakin III impairs the protective urothelial layer, increasing urothelial permeability and neurogenic dysfunction affecting pain and bladder control[6][7]
- Extracellular matrix stiffening — increased ECM stiffness accompanies compromised bladder function in radiation cystitis models[6]
:::warning The Irradiated Tissue Bed Once tissue is irradiated, the damage is permanent and progressive. Late toxicity does not plateau — it continues to evolve over years. Irradiated tissue is characterized by the 3 H's: hypovascular, hypocellular, hypoxic. This has direct implications for reconstruction: grafts fail, suture lines break down, and wound healing is fundamentally compromised. Every reconstructive decision in a previously irradiated field must account for this biology. :::
Dose-Response Relationships
| Parameter | Clinical Correlate |
|---|---|
| Total dose | Higher total dose → greater late toxicity risk |
| Fraction size | Larger fractions (hypofractionation) increase late-tissue biological dose (α/β ratio ~3 Gy for bladder) |
| Volume of bladder irradiated | Bladder V65 and V80 correlate with late grade ≥3 toxicity |
| Urethral dose | Urethral Dmax correlates with stricture risk; dose to membranous urethra particularly important in prostate RT |
| Penile bulb dose | Correlates with erectile dysfunction in some but not all studies[12] |
| Prior pelvic surgery | Reduces tissue tolerance; increases complication rates |
Grading of Radiation Toxicity
Two grading systems are commonly used in the literature:
| Grade | RTOG/EORTC Definition | CTCAE Equivalent |
|---|---|---|
| 1 | Slight epithelial atrophy; minor telangiectasia; microscopic hematuria | Asymptomatic |
| 2 | Moderate urinary frequency; occasional blood-tinged urine; dysuria; moderate hematuria | Symptomatic, limiting instrumental ADL |
| 3 | Severe urinary frequency/dysuria; severe hematuria with clots; catheterization required | Severe, limiting self-care ADL |
| 4 | Necrosis, fistula, obstructive uropathy requiring urinary diversion | Life-threatening |
| 5 | Death | Death |
The pooled 60-month cumulative incidence of grade ≥2 GU toxicity after prostate radiotherapy ranges from 17% (RTOG criteria) to 33% (CTCAE criteria), with specific complications including hematuria (5%), urinary incontinence (12%), and urinary retention (24%).[9]
Urologic Complications in Men
Bladder and Urethral Toxicity
Long-term GU toxicity following prostate radiotherapy includes significant structural and functional complications at 12 years of follow-up:[8]
| Complication | 12-Year Hazard Ratio vs Untreated | 12-Year Cumulative Incidence |
|---|---|---|
| Urethral stricture | 6.49 | — |
| Radiation cystitis | — | 4.7% (vs 0.03% untreated) |
| Urinary incontinence | 2.76 | — |
| Bladder cancer | 2.78 | — |
| Bladder cancer requiring cystectomy | 3.56 | — |
Urethral stricture after prostate radiotherapy is characteristically located at the bulbomembranous junction — the segment receiving the highest urethral dose during prostate treatment. Brachytherapy causes higher stricture rates than EBRT, and combined modality therapy (radical prostatectomy + adjuvant/salvage RT) carries the highest risk.[1][10]
Radiation cystitis (chronic) affects 5–10% of patients treated for prostate, rectal, or gynecological cancers. Severity correlates with radiation dose, fraction size, and bladder volume irradiated.[3] The predominant late manifestation is hemorrhagic cystitis from submucosal telangiectasia. Risk factors include obesity (OR 1.29), smoking (OR 1.27), and diabetes mellitus (OR 1.32), supporting the vascular pathophysiology.[28]
Erectile Dysfunction
Erectile dysfunction (ED) occurs in up to 50% of men after pelvic radiotherapy, with hazard ratios exceeding 2-fold at 12 years and 6-fold at 2 years compared to untreated controls.[8] The mechanism is predominantly vasculogenic — radiation damages the internal pudendal arteries and the cavernous vasculature supplying the corpora cavernosa, producing progressive arterial insufficiency.[12]
ProtecT trial (6-year patient-reported outcomes):[13]
| Treatment | Erections Firm Enough for Intercourse at 6 Years |
|---|---|
| Baseline (all groups) | 67% |
| Radical prostatectomy | 17% |
| Radiotherapy | 27% |
| Active monitoring | 30% |
External beam radiotherapy preserves sexual function better than surgery at 6 years, though both groups show significant decline from baseline. Brachytherapy provides outcomes similar to external beam RT.[14]
Dose to the penile bulb correlates with ED in some studies and is used as a surrogate marker for critical neurovascular structures. Vessel-sparing radiation techniques that reduce dose to the internal pudendal arteries aim to reduce ED rates, though the dose-response relationship is not consistent across all studies.[12]
Urologic Complications in Women
Pelvic Floor Dysfunction
After pelvic radiotherapy for gynecological cancers, women experience high rates of pelvic floor dysfunction that persist years after treatment:[15]
| Symptom | Prevalence |
|---|---|
| Urinary incontinence | 37% |
| — Urgency incontinence | 47% |
| — Stress incontinence | 34% |
| Overactive bladder | 42% |
| Pelvic pain | 30% |
| Anal incontinence | 24% |
| Sexual dysfunction | 19% |
| Defecatory urgency | Increases with longer follow-up |
Vaginal and Sexual Effects
Radiation causes vaginal dryness, fibrosis, shortening, and stenosis through direct mucosal damage, vascular injury, and progressive loss of elasticity. The reported incidence of vaginal stenosis after pelvic radiotherapy ranges from 1.2% to 88% depending on the measurement method used.[16][17]
Objective biomechanical measurements demonstrate significant post-treatment changes:[18]
- Vaginal elasticity: 11.3 post-treatment vs 28.3 pre-treatment
- Vaginal tightening scores: 2.6 vs 16.7 pre-treatment
- Reduced wall mobility and pelvic muscle contraction strength
Temporal course:
- Acute phase: Vaginal mucositis, pain, edema, and ulceration — typically resolves within weeks
- Late phase: Fibrosis, telangiectasia, postcoital bleeding, and dyspareunia; often compounded by radiation-induced ovarian failure causing decreased lubrication and epithelial thinning[16][19]
NCCN guidelines recommend post-radiation vaginal dilator use and vaginal moisturizers for patients with uterine, cervical, and vaginal cancers, though RCT evidence for dilator therapy preventing stenosis remains limited.[20][21][22][17]
Genitourinary Reconstruction After Radiation
Reconstruction in the irradiated field demands a fundamentally different approach than surgery in non-irradiated tissue. The key principle is importing non-irradiated, well-vascularized tissue from outside the radiation field to support repair.
:::note Core Reconstructive Principle in the Irradiated Field Standard techniques applied to non-irradiated tissue frequently fail when applied to irradiated tissue. Grafts take poorly on hypovascular beds. Suture lines break down in hypoxic tissue. Simple anastomosis in a radiation-damaged urethra predictably strictures. Reconstruction requires importing a vascular supply — typically via pedicled or free flap — and must account for the permanently compromised biology of the field. :::
Urethral Stricture Reconstruction
Radiation-induced urethral strictures — particularly bulbomembranous strictures after prostate radiotherapy — represent some of the most challenging cases in reconstructive urology. Patients frequently undergo an average of 4.4 endoscopic procedures attempting to salvage native voiding before definitive reconstruction is pursued.[10]
Buccal mucosal graft urethroplasty demonstrates long-term success rates of 70–100% for post-radiation urethral strictures, despite the theoretical concern about graft take in an irradiated recipient bed.[23][24] The robust submucosal vascularity of buccal mucosa facilitates inosculation even in partially compromised beds.
Anastomotic (excision and primary anastomosis) urethroplasty achieves 85.7% patency in radiation-induced bulbomembranous stenoses, though patients frequently experience persistent complications:[24]
- Storage symptoms: 40%
- Erectile dysfunction: 30%
- Urinary incontinence: 25.7%
In women, dorsal onlay buccal mucosal graft urethroplasty achieves excellent outcomes for post-radiation female urethral strictures.[25]
Robotic approaches are emerging with comparable outcomes and faster recovery.[23]
See also: Urethral Stricture · Ureteral Stricture
Ureteral Reconstruction
Radiation-induced ureteral strictures most commonly involve the distal ureter in the radiation field of gynecological cancers, though any segment can be involved. Diagnosis is often delayed, and bilateral involvement is not uncommon.
Robotic ureteral reconstruction for radiation-induced strictures employs multiple techniques depending on stricture location and length:[26]
| Technique | % Used in Radiation Cohort |
|---|---|
| End-to-end reimplantation | 60% |
| Side-to-side anastomosis | 22.9% |
| Appendiceal interposition | 11.4% |
| BMG ureteroplasty | Adjunct |
| Ileal ureter interposition | Long-segment defects |
Adjunctive procedures are frequently required:
- Psoas hitch / Boari flap — for additional reach to the bladder
- Omental wrap — vascularized tissue support around the anastomosis (critical in irradiated field)
At median 13-month follow-up, 88.2% of cases achieved clinical and radiological success.[26]
End-Stage Bladder Management
For the most severe radiation-induced complications, urinary diversion becomes necessary in approximately one-third of patients with RTOG grade 4 urinary adverse events.[11]
Indications for diversion:[10]
| Indication | Proportion |
|---|---|
| Rectourethral fistula | 37% |
| Devastated outlet | 27% |
| End-stage radiation bladder | 20% |
| Combined pathology | 17% |
Management options include cystectomy with conduit diversion, conduit diversion with bladder preservation, and chronic indwelling suprapubic catheter. Approximately 25% of patients are manageable through conservative or local surgical approaches without diversion.[11]
:::note Conduit in Irradiated Pelvis Ileal conduit creation in the previously irradiated pelvis carries elevated risk: the ileal segment and its mesentery may have received radiation dose, anastomotic leak rates are higher, and the uretero-ileal anastomosis is at risk for stricture. Bringing the conduit through a non-irradiated abdominal wall window and using the most mobile, least-irradiated bowel segment are technical priorities. :::
Management Strategies
Acute Toxicity
| Symptom | Management |
|---|---|
| Irritative/storage (frequency, urgency, dysuria) | Urinary alkalinization; anticholinergics (oxybutynin); beta-3 agonists (mirabegron) |
| Obstructive (hesitancy, weak stream, retention) | α1-adrenergic antagonists (tamsulosin, silodosin) |
| Hematuria | Exclude secondary malignancy; continuous bladder irrigation for clot retention |
Acute reactions generally resolve within 4–6 weeks after treatment completion with urothelial regeneration.[1]
Chronic Radiation Cystitis
Hemorrhagic radiation cystitis requires first excluding secondary malignancy (cystoscopy, urine cytology, imaging) before attributing hematuria to radiation alone. Management is stepwise:[1][27][3]
| Step | Intervention | Notes |
|---|---|---|
| 1 | Cystoscopy + fulguration of telangiectasia | Bipolar or Nd:YAG laser; avoids overdistension |
| 2 | Intravesical alum (1%) | Continuous irrigation; precipitates protein, reduces bleeding |
| 3 | Intravesical formalin (0.5–4%) | Under anesthesia; highly effective but significant risk of vesicoureteral reflux/ureteral injury; requires ureteral protection |
| 4 | Intravesical hyaluronic acid / chondroitin sulfate | Glycosaminoglycan replacement; repairs urothelial barrier |
| 5 | Hyperbaric oxygen therapy (HBO) | 20–40 sessions at 2.0–2.4 ATA; promotes angiogenesis in hypoxic tissue; demonstrated efficacy in RCT[3] |
| 6 | Urinary diversion / cystectomy | Final option; preserved bladder with intractable hemorrhage |
Hyperbaric oxygen (HBO) is the most evidence-supported intervention for refractory radiation cystitis. The 2025 RICH-ART randomized trial demonstrated its efficacy for chronic radiation-induced cystitis with durable long-term follow-up.[3]
Radiation-Induced Sexual Dysfunction
Men:
- Phosphodiesterase-5 inhibitors (PDE5i): First-line; efficacy is reduced compared to non-irradiated patients due to underlying vasculogenic ED
- Penile rehabilitation: Early PDE5i use after radiotherapy may preserve erectile function; vacuum erection devices as adjunct
- Intracavernosal injection therapy: Effective when oral therapy fails
- Penile prosthesis implantation: Highly effective for radiation-induced ED refractory to other therapy; irradiated tissue increases infection risk and surgical complexity
- Vaginal estrogen (when oncologically appropriate): Restores mucosal thickness and lubrication in the setting of radiation-induced ovarian failure
- Vaginal moisturizers and lubricants: Non-hormonal first-line option
- Pelvic floor physical therapy: Addresses musculoskeletal components of dyspareunia and incontinence
- Vaginal dilators: Recommended post-radiation to reduce stenosis progression; evidence for prevention is limited[17]
Technical Radiation Advances Reducing GU Toxicity
| Advance | Mechanism of Toxicity Reduction |
|---|---|
| IMRT / VMAT | Dose conformality reduces bladder neck, proximal urethra, and rectal dose |
| Image-guided RT (IGRT) | Daily imaging reduces setup error; smaller margins needed, sparing adjacent structures |
| Bladder filling protocols | Full bladder during treatment displaces small bowel; empty bladder reduces dose to posterior wall |
| Rectal spacer (SpaceOAR) | Hydrogel injected between prostate and rectum increases separation; reduces rectal dose |
| Dose constraints | Bladder V65 <25%, urethral Dmax <118% of prescription dose (brachytherapy) — institutional dose constraints |
| Proton beam | Bragg peak reduces exit dose; potential advantage in re-irradiation scenarios |
| Adaptive RT | Real-time treatment adaptation based on daily anatomy changes |
Secondary Malignancy Risk
Radiation to the bladder and pelvic organs carries a long-term risk of secondary malignancy:[8]
- Bladder cancer: 12-year hazard ratio 2.78 compared to untreated controls; 3.56-fold increased risk of bladder cancer requiring cystectomy
- Rectal cancer, sarcoma: Rare but documented secondary malignancies within or adjacent to the radiation field
- Absolute risk increase: 0.1–3.8% across studies, with higher rates in younger patients who receive more cumulative radiation over a lifetime[1]
Implication: Long-term surveillance cystoscopy is appropriate in patients with a history of pelvic radiation who present with new hematuria — secondary malignancy must be excluded before attributing symptoms to radiation cystitis.
Quality of Life Impact
Pelvic radiation produces moderate-to-severe symptoms that persist long-term and correlate with measurable reductions in quality of life:[30]
| Symptom Domain | Women | Men |
|---|---|---|
| Bowel urgency | 59% | 45% |
| Urinary urgency | 49% | 46% |
| Sexual dysfunction | 24% | 53% |
These symptoms remain equally prevalent 6–11 years post-treatment as they are 1–5 years post-treatment — there is no natural resolution of late effects over time. Higher symptom burden correlates significantly with increased depression and poorer overall quality of life.[30]
Patient-reported outcomes research emphasizes the importance of transparent pre-treatment counseling about long-term GU sequelae and the desire for structured peer support networks among those experiencing persistent complications.[31]
References
1. Martin JM, Richardson M, Siva S, et al. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. Lancet Oncol. 2022;23(12):e534–e543. PMID 36400097
2. Lobo N, Kulkarni M, Hughes S, et al. Urologic complications following pelvic radiotherapy. Urology. 2018;122:1–9. PMID 30012457
3. Oscarsson N, Rosén A, Müller B, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): long-term follow-up of a randomised controlled, phase 2–3 trial. EClinicalMedicine. 2025;83:103214. DOI
4. Citrin DE, Timmerman RD. Effects of radiotherapy in normal tissue. N Engl J Med. 2026;394(10):996–1009. DOI
5. Denton AS, Clarke NW, Maher EJ. Non-surgical interventions for late radiation cystitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev. 2002;(3):CD001773. PMID 12137636
6. Zwaans BMM, Grobbel M, Carabulea AL, Lamb LE, Roccabianca S. Increased extracellular matrix stiffness accompanies compromised bladder function in a murine model of radiation cystitis. Acta Biomater. 2022;144:221–229. PMID 35344984
7. Zwaans BMM, Carabulea AL, Bartolone SN, et al. Voiding defects in acute radiation cystitis driven by urothelial barrier defect through loss of E-cadherin, ZO-1 and uroplakin III. Sci Rep. 2021;11(1):19277. PMID 34584186
8. Unger JM, Till C, Tangen CM, et al. Long-term adverse effects and complications after prostate cancer treatment. JAMA Oncol. 2024. PMID 39356502
9. David R, Buckby A, Kahokehr AA, et al. Long-term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26(1):8–15. PMID 35869175
10. Faris SF, Milam DF, Dmochowski RR, Kaufman MR. Urinary diversions after radiation for prostate cancer: indications and treatment. Urology. 2014;84(3):702–706. PMID 24931512
11. Mayer EN, Tward JD, Bassett M, et al. Management of Radiation Therapy Oncology Group grade 4 urinary adverse events after radiotherapy for prostate cancer. BJU Int. 2017;119(5):700–708. PMID 27681893
12. Lee JY, Spratt DE, Liss AL, McLaughlin PW. Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy. Lancet Oncol. 2016;17(5):e198–208. PMID 27130548
13. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–1437. PMID 27626365
14. Mullins BT, Basak R, Broughman JR, Chen RC. Patient-reported sexual quality of life after different types of radical prostatectomy and radiotherapy. Cancer. 2019;125(20):3657–3665. PMID 31314157
15. Pérez CDA, Rocha AKL, Volpato MP, et al. Prevalence of pelvic floor dysfunction in women after pelvic radiotherapy: systematic review and meta-analysis. Int Urogynecol J. 2026. DOI
16. Denton AS, Maher EJ. Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy. Cochrane Database Syst Rev. 2003;(1):CD003750. PMID 12535480
17. Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev. 2014;(9):CD007291. PMID 25198150
18. Matanes E, Linder R, Lauterbach R, et al. The impact of radiation therapy on vaginal biomechanical properties. Eur J Obstet Gynecol Reprod Biol. 2021;264:36–40. PMID 34217019
19. Metzger ML, Meacham LR, Patterson B, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol. 2013;31(9):1239–1247. PMID 23358971
20. National Comprehensive Cancer Network. Uterine Neoplasms. NCCN Clinical Practice Guidelines in Oncology. Version 2025.
21. National Comprehensive Cancer Network. Cervical Cancer. NCCN Clinical Practice Guidelines in Oncology. Version 2025.
22. National Comprehensive Cancer Network. Vaginal Cancer. NCCN Clinical Practice Guidelines in Oncology. Version 2025.
23. Sterling J, Rahman SN, Varghese A, Angulo JC, Nikolavsky D. Complications after prostate cancer treatment: pathophysiology and repair of post-radiation urethral stricture disease. J Clin Med. 2023;12(12):3950. PMID 37373646
24. Rourke K, Kinnaird A, Zorn J. Observations and outcomes of urethroplasty for bulbomembranous stenosis after radiation therapy for prostate cancer. World J Urol. 2016;34(3):377–382. PMID 26272217
25. Gupta P, Kalra S, Dorairajan LN, et al. Dorsal onlay buccal mucosal graft urethroplasty in post-radiation female urethral stricture: a technical appraisal with outcomes. Urology. 2021;156:321. PMID 34116110
26. Asghar AM, Lee Z, Lee RA, et al. Robotic ureteral reconstruction in patients with radiation-induced ureteral strictures: experience from the Collaborative of Reconstructive Robotic Ureteral Surgery. J Endourol. 2021;35(2):144–150. PMID 32883115
27. Skolarus TA, Wolf AM, Erb NL, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64(4):225–249. PMID 24916760
28. Bologna E, Licari LC, Franco A, et al. Incidence and management of radiation cystitis after pelvic radiotherapy for prostate cancer: analysis from a national database. Urology. 2024;191:86–92. PMID 38885827
29. Hickey M, Basu P, Sassarini J, et al. Managing menopause after cancer. Lancet. 2024;403(10430):984–996. PMID 38458217
30. Adams E, Boulton MG, Horne A, et al. The effects of pelvic radiotherapy on cancer survivors: symptom profile, psychological morbidity and quality of life. Clin Oncol (R Coll Radiol). 2014;26(1):10–17. PMID 24094630
31. Leng L, Maremanda A, Li KD, et al. Genitourinary radiation injury: a mixed-methods study exploring patient-reported outcomes and impact on quality of life. Urology. 2025. DOI